Loading...

Home
ETF
BFRIW

BFRIW

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

BFRIW News

BIOFRONTERA INC PLANS TO SUBMIT PHASE 2B DATA FOR AMELUZ PDT TO FDA IN Q3 2026

BIOFRONTERA INC - AMELUZ PDT SHOWS POSITIVE SAFETY RESULTS IN PHASE 2B TRIAL

BIOFRONTERA INC - PHASE 2B STUDY DEMONSTRATES SIGNIFICANTLY LOWER INFLAMMATORY ACNE LESIONS WITH AMELUZ PDT

BIOFRONTERA INC. ANNOUNCES ENCOURAGING PHASE 2B RESULTS FOR CONTINUED DEVELOPMENT OF AMELUZ® PHOTODYNAMIC THERAPY IN TREATING MODERATE TO SEVERE ACNE VULGARIS

BIOFRONTERA INC ANTICIPATES SUPPLEMENTAL NDA FILING FOR EXTREMITY, NECK, AND TRUNK INDICATION IN Q3 2026

Feb 17 2026moomoo

BIOFRONTERA INC. REPORTS COMPLETION OF DATABASE LOCK FOR PHASE 1 PHARMACOKINETICS STUDY OF AMELUZ® IN TREATING ACTINIC KERATOSES ON TRUNK AND EXTREMITIES

Feb 17 2026moomoo

BIOFRONTERA INC - FDA Establishes PDUFA Deadline for September 28, 2026

Feb 11 2026moomoo

BIOFRONTERA CONFIRMS FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AMELUZ® PDT IN TREATING SUPERFICIAL BASAL CELL CARCINOMA

Feb 11 2026moomoo

BIOFRONTERA INC PLANS TO FILE SNDA WITH FDA IN Q3 2026

Feb 09 2026moomoo

BIOFRONTERA INC Reports 73.1% Lesion Clearance in FAS and 80.3% in PPS

Feb 09 2026moomoo

BIOFRONTERA INC - AMELUZ PDT SHOWS 45.6% CLEARANCE RATE IN PHASE 3 TRIAL

Feb 09 2026moomoo

BIOFRONTERA INC - PRIMARY ENDPOINT MET WITH FULL CLEARANCE RATE OF AK LESIONS

Feb 09 2026moomoo

BIOFRONTERA REPORTS SUCCESSFUL PHASE 3 STUDY RESULTS FOR AMELUZ® PDT TREATMENT OF ACTINIC KERATOSES ON EXTREMITIES, NECK, AND TRUNK, ACHIEVING PRIMARY ENDPOINT

Feb 09 2026moomoo

Biofrontera Inc. Announces Financial Results for Q3 2025 and Offers Business Update

Nov 13 2025Newsfilter

Biofrontera Inc. Completes Acquisition of All US Assets for Ameluz® and RhodoLED® from Biofrontera AG

Oct 23 2025Newsfilter

Biofrontera Inc. Set to Attend Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Sep 26 2025Newsfilter